Table 1

Prevalence of reduced kidney function (based on eGFR values only) in the Chilean population aged 18 years and older

CKD stage*eGFR†
(mL/min/1.73 m2)
Prevalence
ENS 2009–2010ENS 2016–2017
N% (95% CI)N% (95% CI)
Stage G1‡≥90329377.6.0 (75.5 to 79.6)351177.9 (75.9 to 79.8)
Stage G2‡60–89110419.9 (18.0 to 21.9)130118.8 (17.1 to 20.8)
Stage G3a45–591221.6 (1.2 to 2.3)1762.1 (1.6 to 2.8)
Stage G3b30–44470.5 (0.3 to 0.8)650.6 (0.4 to 0.8)
Stage G415–29130.2 (0.1 to 0.4)200.4 (0.2 to 0.8)
Stage G5<1540.1 (0.0 to 0.4)110.1 (0.1 to 0.4)
CKD stages G3a–G51862.5 (1.9 to 3.2)2723.2 (2.6 to 4.0)
  • *Presence of reduced kidney function or CKD (stages G3a–G5) indicated by eGFR <60 mL/min/1.73 m2 in accordance with KDIGO guidelines:5 shown by cells in dark grey shading. G2: mildly decreased eGFR; G3a: mildly to moderately decreased; G3b: moderately to severely decreased; G4: severely decreased and G5: kidney failure.

  • †eGFR (measured in mL/min/1.73 m2) determined by CKD-EPI equation.

  • ‡Stages G1 and G2 CKD are diagnosed by the presence of raised albuminuria in the presence of normal to high eGFR. Thus, for the purposes of this table, using eGFR values only, these individuals have been classified together with the majority with no CKD.

  • CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; ENS, Encuesta Nacional de Salud; KDIGO, Kidney Disease Improving Global Outcomes.